×
About 14,889,585 results

American Heart Association Hypertension Guideline Toolkit
http://aha-clinical-review.ascendeventmedia.com/books/aha-high-blood-pressure-toolkit/
American Heart Association

AHA High Blood Pressure Toolkit

Improving Shingles Vaccination Rates in Family Medicine.
https://doi.org/10.12788/jfp.0218
The Journal of Family Practice; Luther JS

Aug 26th, 2021 - At the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness amo...

Alpha1-antitrypsin deficiency: New therapies on the horizon.
https://doi.org/10.1016/j.coph.2021.06.001
Current Opinion in Pharmacology; Remih K, Amzou S et. al.

Jul 14th, 2021 - Alpha1-antitrypsin deficiency (AATD) is caused by mutations in the SERPINA1 gene, coding for alpha1-antitrypsin (AAT). AAT is synthesised mainly in the liver and is released into bloodstream to protect tissues (particularly lung) with its antiprotease activity. The homozygous Pi∗Z mutation (Pi∗ZZ genotype) is the predominant cause of severe AATD. It interferes with AAT secretion thereby leading...

Central and peripheral arterial diseases in chronic kidney disease: conclusions from a ...
https://doi.org/10.1016/j.kint.2021.04.029
Kidney International; Johansen KL, Garimella PS et. al.

May 8th, 2021 - Chronic kidney disease (CKD) affects about 10% of all populations worldwide, with about 2 million people requiring dialysis. Although patients with CKD are at high risk of cardiovascular disease and events, they are often underrepresented or excluded in clinical trials, leading to important knowledge gaps about how to treat these patients. KDIGO (Kidney Disease: Improving Global Outcomes) conve...

Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 4th, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

ESMO Virtual Congress 2020 Science Weekend Program
https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/session/calendar

Sep 19th, 2020 - ESMO Virtual Congress 2020 Science Weekend Online Program

ESMO Guidelines: COVID-19 Adapted Recommendations Slide Sets
https://www.esmo.org/guidelines/covid-19-adapted-recommendations-slide-sets

Sep 19th, 2020 - The core content of each COVID-19 adapted recommendation is presented in a user-friendly format ready for you to use in your own presentations, both to illustrate your own cases and research, as well as for educational purposes. Please note that while you may use slides individually from the sets for personal use, it is strictly forbidden to alter or hide any of the content, the ESMO logo, the ...

ESMO Virtual Congress 2020: Abstracts
https://www.esmo.org/meetings/esmo-virtual-congress-2020/abstracts

Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...

ESMO Virtual Congress 2020: Exhibition
https://www.esmo.org/meetings/esmo-virtual-congress-2020/exhibition

Sep 19th, 2020 - With the new virtual platform, the aim is twofold: on one side to offer an experience which will be able to meet the needs of the many eager to find a fruitful learning opportunity; on the other, we are committed to still offer an engaging networking space, all delivered via state-of-the-art technology. Further information in this regard will be published progressively on this webpage soon.

ESMO: COVID-19 and Cancer
https://www.esmo.org/covid-19-and-cancer?hit=ehp

Sep 19th, 2020 - Updates, guides, webinar series, recommendations, more.

ESMO Webinar Series: Managing Patients in the COVID-19 Era
https://www.esmo.org/meetings/esmo-webinar-series/managing-patients-in-the-covid-19-era

Sep 19th, 2020 - This Webinar series has been organised with the aim to share the ESMO adapted recommendations for cancer patient management during the COVID-19 pandemic. These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.

ESMO Virtual Congress 2020: Program
https://www.esmo.org/meetings/esmo-virtual-congress-2020/programme

Sep 19th, 2020 - The ESMO Virtual Congress 2020 Programme is now online! The ESMO Virtual Congress 2020 will be the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.

ESMO Virtual Congress 2020: ESMO Colloquia
https://www.esmo.org/meetings/esmo-virtual-congress-2020/esmo-colloquia

Sep 19th, 2020 - The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

ESMO Virtual Congress 2020: FAQs
https://www.esmo.org/content/download/313751/6378320/ESMO-Virtual-Congress-2020-FAQs.pdf

Sep 19th, 2020 - ESMO Virtual Congress 2020: Frequently Asked Questions

ESMO
https://www.esmo.org/

Sep 19th, 2020 - EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY The leading professional organisation for medical oncology

ESMO COVID-19 Full Coverage
https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage

Sep 19th, 2020 - The COVID-19 pandemic has brought new challenges to clinical practice and research in oncology. ESMO is reporting on the current situation by news and KOLs experiences, and has gathered useful resources to keep medical oncologists updated.

ESMO Virtual Congress 2020: Meeting
https://www.esmo.org/meetings/esmo-virtual-congress-2020

Sep 18th, 2020 - Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track. Take part in Europe's most prestigious platform for oncology stakeholders.

ESMO: COVID-19 and Cancer Care in the ESMO Journals
https://www.esmo.org/covid-19-and-cancer/covid-19-and-cancer-care-in-the-esmo-journals

Sep 18th, 2020 - In this page you can find the articles related to COVID-19 disease in the context of cancer care management as published in the ESMO flagship journal, the Annals of Oncology and the ESMO Open.

ESMO Guideline for Cancer Patient Management During the COVID-19 Pandemic
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp

Sep 18th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges of treating patients, while ensuring their rights, safety and wellbeing.

ACR 2020 Permissions and Reprints
https://www.rheumatology.org/Annual-Meeting/Abstracts/Permissions-and-Reprints

Sep 7th, 2020 - ACR Convergence, the ACR's annual meeting, is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, ...